New shot could tame severe eczema in teens
NCT ID NCT07309055
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests an experimental drug called SHR-1819 in about 200 teenagers aged 12 to 17 with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo injection. The study measures how well the drug clears skin rashes and reduces itching over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1819 injection
- What this could lead to
- If successful, this could provide a new treatment option for teenagers with severe eczema, reducing skin inflammation and itching.
- What could go wrong
- This is still an experimental drug, and its safety and effectiveness are not yet proven. Side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110002, China
-
Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200092, China